key: cord-1017328-19l4yqeu authors: Nace, D. A.; Kip, K. E.; Peck Palmer, O. M.; Shurin, M. R.; Mulvey, K.; Crandall, M.; Kane, A. L.; Lukanski, A.; Kip, P. L.; Wells, A. L. title: Antibody Responses in Elderly Residential Care Persons following COVID-19 mRNA Vaccination date: 2021-04-10 journal: nan DOI: 10.1101/2021.04.07.21254925 sha: 966b12de191498c833eb930643f6ec9c3a0981ca doc_id: 1017328 cord_uid: 19l4yqeu Objective COVID-19 disproportionately impacts older adults residing at long-term care facilities. Data regarding antibody response to COVID-19 vaccines in this population is limited. Our objective was to quantify the presence and magnitude of antibody response in older, vaccinated residents at assisted living, personal care, and independent living facilities. Design A cross-sectional quality improvement study was conducted March 15-April 1, 2021 in the Pittsburgh region. Setting and Population Participants were volunteers at assisted living, personal care, and independent living facilities, who received mRNA COVID-19 vaccine. Conditions that obviate immune responses were exclusionary criteria. Methods Sera were collected to measure IgG anti-SARS-CoV-2 antibody level with reflex to total anti-SARS-CoV-2 immunoglobulin levels. Descriptive statistics, Pearson correlation coefficients, and multiple linear regression analysis were performed to evaluate relationships between factors potentially associated with antibody levels. Results All participants (N=70) had received two rounds of vaccination for COVID-19 and were found to have antibodies to SARS-CoV-2. There was wide variation in relative levels of antibodies as determined by extinction coefficients. Antibody levels trended lower in male sex, advanced age, steroid medications, and longer length of time from vaccination. Conclusions and Implications Higher functioning long-term care residents mounted detectable antibody responses when vaccinated with COVID-19 mRNA-based vaccines. This study provides preliminary information on level of population risk of assisted living, personal care, and independent living residents which can inform reopening strategies. Data suggests some degree of immunity is present during the immediate period following vaccination. However, protective effects of such vaccination programs remain to be determined in larger studies. Clinical protection is afforded not just by pre-formed antibody levels, but by ongoing adaptive immunity, which is known to be decreased in older individuals. Thus, the implications of these levels of antibodies in preventing COVID-19 disease must be determined by clinical follow-up. Higher functioning long-term care residents mounted detectable antibody responses when 25 vaccinated with COVID-19 mRNA-based vaccines. This study provides preliminary information 26 on level of population risk of assisted living, personal care, and independent living residents 27 which can inform reopening strategies. Data suggests some degree of immunity is present during 28 the immediate period following vaccination. However, protective effects of such vaccination 29 programs remain to be determined in larger studies. Clinical protection is afforded not just by 30 pre-formed antibody levels, but by ongoing adaptive immunity, which is known to be decreased 31 in older individuals. Thus, the implications of these levels of antibodies in preventing COVID-19 32 disease must be determined by clinical follow-up. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 10, 2021. ; https://doi.org/10.1101/2021.04.07.21254925 doi: medRxiv preprint support data capture for research and quality improvement studies, providing 1) an intuitive 81 interface for validated data capture; 2) audit trails for tracking data manipulation and export 82 procedures; 3) automated export procedures for seamless data downloads to common statistical 83 packages; and 4) procedures for data integration and interoperability with external sources. 9 Data was collected on vaccination status (number of doses, dates, and type of vaccine), medical 85 conditions, and current medications. Level of frailty was assessed in participants using self- Total assay (ADIVA Centaur XP analyzer, Munich, Germany; Siemens-C). 13, 14 The Beckman 96 Coulter assay uses S1 Spike antigens as capture and anti-IgG as reporter; the Siemens uses S1 97 Spike antigens as both capture and reporter and thus IgM antibodies are detected and at a higher . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 10, 2021. ; https://doi.org/10.1101/2021.04.07.21254925 doi: medRxiv preprint Descriptive statistics for baseline population characteristics were calculated as means, 104 standard deviations, and frequencies. Pearson correlation coefficients were calculated between 105 age and antibody level, and between days since vaccination and antibody level. We also 106 performed multiple linear regression modeling using stepwise entry criteria of p < 0.20 to 107 identify factors potentially associated with antibody levels. Analyses were performed using SAS, Table 1 ). 16 Presented in Table 1 , a total of 70 volunteers participated, age range was 62-97 years old 115 with almost half in their 80s (49.3%) and the rest split between younger (22.5%) and older 116 (28.2%). Two-thirds were female (60%) and almost all participants were white (97.1%). The 117 frailty indices indicated moderate to high functioning. All participants provided sera to be tested for antibodies to SARS-CoV-2, had undergone 120 two rounds of vaccination (Moderna 98.6%, Pfizer 1.4%) within the prior 50 days, and one in six 121 had recovered from COVID-19 infection (15.7%). Antibody levels were determined using two 122 FDA Emergency Use assays. All participants were found to have antibodies to SARS-CoV-2; 123 one was deemed non-reactive by the Beckman Coulter assay, having an extinction coefficient < 124 1, but was assessed as reactive by the more sensitive ADIVA Centaur assay. 13 There is wide 125 variation in relative levels of antibodies as determined by extinction coefficients. While the 126 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2021. ; https://doi.org/10.1101/2021.04.07.21254925 doi: medRxiv preprint sample size is modest, which hinders statistical power, we found that antibody levels trended 127 lower with male sex (standardized beta coefficient (β)=-0.11, p=.33) (Figure 1 ), advanced age 128 (β=-0,18, p=.11), current use of steroids (β=-0,22, p=.07), and longer length of time from 129 vaccination (β=-0.13, p=.28) (Figure 2) . In participants who previously tested positive for The modest sample limits the precision in estimates and conclusions drawn, particularly in 148 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2021. ; https://doi.org/10.1101/2021.04.07.21254925 doi: medRxiv preprint stratified analyses. Participants were volunteers and likely to be healthier than non-participants, 149 and individuals with known immunosuppression were excluded. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2021. Previously told had COVID-19, %, (n) 15.7 (11) 11.9 (5) 21,4 (6) Currently taking a steroid medication, %, (n) 8.6 (6) 9.5 (4) 7.1 (2) Days from first vaccine to antibody sample, mean . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2021. ; https://doi.org/10.1101/2021.04.07.21254925 doi: medRxiv preprint participants. Describe methods of follow-up Case-control study -Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study -Give the eligibility criteria, and the sources and methods of selection of participants . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 10, 2021. Discussion, Page 7-8 The point of the conclusion is not to rewrite the whole project, but to give an overview of how the whole project was conducted, what it achieved, and some personal reflections. Other Information Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Page 8 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 10, 2021. ; https://doi.org/10.1101/2021.04.07.21254925 doi: medRxiv preprint COVID-19 Nursing Home Data Nursing homes, once hotspots, far outpace U.S. in COVID declines Nursing Home Visitation -COVID-19 QSO-20-39-NH REVISED Interim recommendations for communal activities and visitation in post-acute and long-term care facilities Recommendations for welcoming back nursing home visitors during the COVID-19 pandemic: Results of a Delphi panel COVID-19 recommendations for assisted living: Implications for the future Finding the right balance: An evidenceinformed guidance document to support the re-opening of Canadian nursing homes to family caregivers and visitors during the coronavirus disease 2019 pandemic Research electronic data capture (REDCap) -A metadata-driven methodology and workflow process for providing translational research informatics support The REDCap consortium: Building an international community of software partners Assessing self-maintenance: Activities of daily living, mobility, and instrumental activities of daily living Progress in the development of the index of ADL Assessment of older people: Self-maintaining and instrumental activities of daily living Performance of commercially available EUA SARS-CoV-2 antibody assays in critically ill and mildly symptomatic patients assessed at a large academic medical center SARS-CoV-2 serologic immune response in exogenously immunosuppressed patients The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): Revised publication guidelines from a detailed consensus process COVID-19 and the Immune System Immune response in COVID-19: A review